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Abstract
Introduction: Metastasis represents a major adverse step in the progression of breast carcinoma. Lymph node
invasion is the most relevant prognostic factor; however little is known on the molecular events associated with
lymph node metastasis process. This study is to investigate the status and role of methylation in lymph node
metastatic tumors.
Materials and methods: Bisulfite pyrosequencing is used to screen 6 putative tumor suppressor genes (HIN-1,
RASSF1A, RIL, CDH13, RARb2 and E-cadherin) in 38 pairs of primary breast tumors and lymph node metastases.
Results: We found that HIN-1, CDH13, RIL, RASSF1A and RARb2 were frequently methylated both in primary and
metastatic tissues (range: 55.3%~89.5%). E-cadherin was not frequently methylated in either setting (range: 18.4%
~23.7%). The methylation status of HIN-1, CDH13, RIL, and RARb2 in lymph nodes metastasis were correlated with
that in primary tumors. The Pearson correlation values ranged from 0.624 to 0.472 (p values < 0.01 to 0.001).
Interestingly, we observed an association between HIN-1 methylation and hormone status in metastatic lymph
nodes. Hypermethylation of HIN-1 in metastasis lymph nodes was significantly associated with expression of ER
(odds ratio, 1.070; P = 0.024) and with PR (odds ratio, 1.046; P = 0.026).
Conclusions: This study suggests that hypermethylation of tumor suppressor genes is extended from primary to
metastatic tumors during tumor progression.
Background
Breast carcinoma is the most common malignancy
among women worldwide. Metastasis represents an
important step in the progression of fatal disease [1].
Metastases are formed by cancer cells from the primary
tumor mass that travel through blood and lymphatic
vessels to colonize lymph nodes, bone, lung, liver and
brain. Complex genetic and epigenetic alterations affect
the efficiency of each step in tumor progression. Clinical
detection of distant metastasis is uncommon at presen-
tation, but regional lymph node metastases are detected
more frequently and correlate with the risk of subse-
quent recurrence at distant sites. Molecular analysis of
metastatic lesions is gradually increasing our
understanding of the events underlying the distant
spread of breast cancer cells from primary cancers.
Genetic changes that occur in metastatic cells have
been studied at the level of individual genes, tissue speci-
fic profiles and whole genome approaches [2]. In general,
metastases and primary cancers have exhibited very simi-
lar expression signatures. The resemblance between pri-
mary and secondly metastasis lymph nodes provide
evidence that the fundamental biological processes which
shape the emergence of the metastatic phenotype have
some underlying homologies. But some reports revealed
a small number of genes that are differentially expressed
between primary and metastasis even there were discre-
pancies in different studies, indicating potential mechan-
istic importance during metastasis event [2-5].
By contrast, epigenetic alterations in metastases are
less characterized than genetic changes in primary
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breast primary tumors has been well-documented [6],
but only small sets of genes have been shown to be
methylated both in the primary tumor and in breast
cancer metastasis. For example, down-regulation of
tumor suppressor gene FEZ1/LZTS1involves promoter
methylation and has been found in lymph node metas-
tases [7]. Epigenetic silencing of DFNA5, encoding che-
mokine CXCL12, may contribute to the metastatic
progression of breast carcinomas [8-10]. A higher preva-
lence of E-Cadherin, RASSF1A, RAR-b2, APC, TWIST
and GSTP1 methylation in primary cancers has been
associated with sentinel lymph node metastasis [11].
There are, however, only few studies that compare
methylation profiles of metastases with those of the
matched primary breast cancer. Metge et al. reported
that 45% of the primary tumors and 60% of the matched
lymph node metastases displayed hypermethylation of
the BRMS1 promoter [12]. Mehrotra found that lymph
node metastasis had a trend of high prevalence of
methylation compared to the primary breast carcinoma
[13]. In addition, epigenetic silencing of CST6 is more
frequently observed in metastatic lesions than in pri-
mary cancers [14]. Furthermore, Rodenhiser et al [9]
generated more intense methylation signatures related
in lymph node metastasis using a highly metastatic var-
iant (MDA-MB-468GFP-LN; 468LN) of a poorly meta-
static MDA-MB-468GFP human breast adenocarcinoma
cell line [15]. Most studies have used non-quantitative
assays of methylation that can provide only the preva-
lence of methylation in primary and metastatic lesions.
A quantitative comparison of methylation levels for spe-
cific genes in primary and metastatic cancers has gener-
ally not been performed.
Our previous study demonstrated that 5 putative
tumor suppressor genes (HIN-1, RASSF1A, RIL, CDH13,
RARb2) were frequently methylated in primary breast
cancers. We also identified two patterns of methylation
that correlated either positively (HIN-1/RASSF1A)o r
negatively (RIL/CDH13) with ER/PR status [16]. We
hypothesized that if silencing of these suppressor genes
were important for tumor progression, hypermethylation
of their promoters would be observed in lymph node
metastasis at least as often and possibly more frequently
than in the primary tumor. To test this hypothesis, we
used bisulfite pyrosequencing to determine methylation
of the 5 putative tumor suppressor genes as well as
another metastasis-related gene E-cadherin in 38 pairs
of primary breast tumors and lymph node metastases.
We found that five of the 6 genes were frequently
methylated at both sites and similar levels of methyla-
tion were found in lymph node metastases and in the
primary cancers.
Methods
Tissue samples
Matched primary breast cancers and their lymph node
metastases were obtained from 38 patients who under-
went surgery between 1989 and 2007 at the Fondazione
IRCCS Istituto Nazionale dei Tumori (Milan, Italy).
Thirty four normal breast epithelial controls were pro-
vided by the Breast Cancer Tumor Bank at U.T.M.D.
Anderson Cancer Center. These normal breast tissues
were from breast cancer patients who had undergone
surgery in 2004 to 2005, all normal samples were col-
lected at least 3 cm away from the site at which the
tumor was sampled and confirmed its normality by two
pathologists. All tissue samples were obtained after
receiving informed consent, according to institutional
rules. The study was approved by the Medical Ethics
Committee of the Fondazione IRCCS Istituto Nazionale
dei Tumori (Milan, Italy) and the Institutional Review
Board of the University of Texas, M.D. Anderson Can-
cer Center. Samples were grossly dissected, frozen
within 1 hour of surgery, and stored at -80°C.
Studies on matched primary tumors and their metas-
tastic lymph nodes from the same patients are rare and
severely limited in the number of samples because of
the difficulties of obtaining suitable specimens. The 38
breast cancer samples with their paired lymph node
metastases of the present study were selected from over
1500 specimens from human breast cancer patients by
careful screening of clinical criteria and histopathologi-
cal features. The criteria of selection of paired primary
tumor and lymph nodes were the following: lymph
nodes with enough tumor tissue for both diagnosis and
research, presence of a single primary tumor and lymph
nodes removed in the same surgery or in a following
surgery no more than 2 month later. The lymph node
samples often contained only benign tissues, massive
infiltration of inflammatory cells or necrotic tumors.
Some metastasis lymph nodes contained small percen-
tage of malignant tumor cells. Thus, less than 50% of
samples collected were considered of quality suitable for
molecular analysis.
The chosen samples were confirmed to contain suffi-
cient tumor tissue for methylation analysis and to be
free of necrotic and fibrous material. The first 10 μm
frozen section from the block face was stained with
hematoxylin and eosin for pathological assessment. Two
pathologists examined each section and independently
assessed the percentage area occupied by the malignant
cells. The results were pooled for each piece of tissue
and averaged to obtain final values. The lymph nodes of
2 cases (case 19 and case 21) were confirmed to contain
only inflammatory cells. Thus these 2 cases were
excluded and left 38 pairs of matched primary tumors
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in pairs of primary and metastastic lymph nodes were
comparable, ranging from 60%-80%. As sample availabil-
ity was highly limiting, the collected cohort represents a
variety of tumor types, pathological characteristics and
clinical treatments.
Immunohistochemical analysis
ER and PR status was determined on primary tumors by
immunoperoxidase staining using ER-ICA/PGR-ICA
assay (Abbott, Abbott Park, Illinois) according to the
manufacturer’s recommendations. Tumors were consid-
ered receptor-positive if more than 10% of malignant
cells showed nuclear staining.
HER-2/neu status was determined on both primary
breast carcinomas and metastastic lymph nodes speci-
mens by immunohistochemistry using A0485 Polyclonal
rabbit anti-Human c-erbB-2 antibody (Dako, Denmark).
Immunoperoxidase assays were carried out by a sensi-
tive peroxidase-streptavidinm e t h o do nf o r m a l i n - f i x e d ,
paraffin-embedded sections of breast carcinomas. Briefly,
1-2 μm consecutive sections were cut, deparaffinized,
rehydrated, and pretreated using the heat-induced epi-
tope retrieval method. Endogenous peroxidase activity
was blocked by 0.3% hydrogen peroxide in methanol for
30 min. After several washes in PBS and treatment with
normal goat serum (1:50) for 30 min at room tempera-
ture, sections were incubated overnight at 4°C with pri-
mary monoclonal antibody, followed by biotinylated
anti-mouse IgG and streptavidin conjugated horseradish
peroxidase (Dako, Denmark). Peroxidase activity was
detected using 3,3’-diaminobenzidine as substrate. Nega-
tive controls were incubated without primary antibody.
Staining was quantified using a score of 0, 1, 2, 3 and
3+ tumors were considered as HER2 positive tumors.
DNA extraction and sodium bisulfite treatment
Genomic DNA was extracted from 50 mg portions of
each frozen tissue sample of primary and metastatic tis-
sues using a Dneasy tissue kit (QIAGEN, Valencia, CA)
and quantitated spectrophotometerically. Bisulfite treat-
ment of 1-2 μg of genomic DNA was performed as pre-
viously described [17].
Genes studied and Pyrosequencing methylation analysis
Five tumor suppressor genes: RASSF1A, HIN-1
(SCGB3A1), RARb2, CDH13, RIL (PDLIM4) were
selected for this study, as they are frequently methylated
in primary breast carcinomas [16]. Another metastasis-
related gene E-cadherin (CDH1) also included in this
study.
Global methylation was estimated by testing methyla-
tion level of LINE1 repetitive elements. Bisulfite pyrose-
quencing was used to detect methylation of all 7 genes.
The primers for pyrosequencing and PCR conditions are
descried previously [13]. Two to six CpG sites were stu-
died for each particular CpG island. Bisulfite-treated
DNA (1 μl) was amplified in 50 μl of reaction mixture,
containing primers and 0.2 units of Tag polymerase
(New England Biolabs, Ipswich, MA). For the amplifica-
tion of HIN-1, RARb2, CDH1,w eu s e dau n i v e r s a lp r i -
mer approach [18].
The PCR product was purified and methylation was
quantitated using the PSQ HS 96A pyrosequencing sys-
tem and Pyro gold reagents (Biotage, Westborough,
MA). Methylation data are presented as the percentage
of average methylation in all observed CpG sites. To set
the controls for pyrosequencing, we used cancer cell
lines and normal cells that were consistently positive or
negative with stable levels of methylation. In this study,
each PCR assay included a positive control (the MDA-
MB-231 breast cancer cell line, which is highly methy-
lated in most genes) and a negative control (normal
breast epithelial cells, HMEC231, which are unmethy-
lated in each of the six genes, but methylated in LINE1).
Accuracy, reproducibility and quantitation of bisulfite
pyrosequencing results were evaluated as described [16].
Analysis of expression data from Ellsworth dataset
Expression data of RASSF1A, RARb2,E - c a d h e r i n
(CDH1), CDH13, RIL (PDLIM4) genes were extracted
from Ellsworth’s dataset [3] containing microarray data
from microdissected tumor cells of 20 primary tumors
and their corresponding lymph node metastasis analyzed
on Affimetrix HG U133A 2.0 arrays. HIN-1 was absent
in the dataset. RIL, RARb2 and E-Cadherin, genes were
recognized by multiple probesets. Two-sample t test was
used to compare value of gene expression in primary
tumors and lymph node metastasis.
Statistical methods and analysis
Descriptive analyses were performed first for exploratory
purposes. Binomial exact test was used for paired com-
parison. Spearman’s correlation coefficient was used to
assess the relationship between two continues variables.
Pearson Chi-square tests or Fisher tests were used to
assess the association between two categorical variables.
Two-sample t test was applied to compare the means of
gene methylation between tumor characteristics. Multi-
variate logistic regression was performed to assess
whether the various levels of gene methylation were
associated with the ER, PR, HR, or HER-2/neu status.
We used Cox model for survival analysis to assess
whether the various levels of gene methylation were
associated with disease free survival and overall survival.
All reported p values are two-sided and considered sta-
tistically significant if p < 0.05. Analyses were performed
using Stata 8.0 software.
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Clinical and pathological characteristics of breast cancer
cohort of patients
Thirty-eight cases of primary tumor and the respective
metastatic axillary lymph node were selected using the
criteria listed in Materials and Methods. The clinico-
pathologic features of 38 cases are presented in Table 1
and Additional file 1 Table S1. The average age at diag-
nosis was 59 years (ranged 35-84 years), which was
comparable with that of normal controls (average age
was 60 years, ranged 29-80 years). Twenty eight cases
were ductal carcinomas, 4 were lobular carcinomas, 4
were mixed and 2 were apocrine and neuroendocrine
cancers. The ER/PR status was assessed in all primary
tumors: 79% of cases were ER positive, whereas 60%
were PR positive. HER-2/neu was overexpressed in 26%
of primary tumors and 33% in metastatic lymph nodes.
Thirty-four patients were followed up from 1 year to 10
years, whereas 4 cases were lost.
Two pathologists reviewed all samples independently;
the proportion of malignant cells in each pair of samples
was comparable, with 34 pairs showing more than 80%
malignant cells. The representative photographs of fro-
zen sections of two primary tumors and their matching
lymph node metastasis confirmed the high quality of
samples (Figure 1)
Methylation of putative suppressor genes
Using pyrosequencing, we measured the methylation
status of 6 putative tumor-suppressor genes HIN-1,
CDH13, RIL, RASSF1A, RARb2, and E-cadherin. Overall,
38 pairs of primary and metastatic breast cancers were
assayed. The sample mean plus two times the standard
deviation of the pooled normal samples was used to
choose the following cutoffs: HIN-1 (10.9), CDH13 (10),
RIL (16.9), RASSF1A (10), RARb2 (10), E-cadherin (10).
Table 2 showed that HIN-1, CDH13, RIL, RASSF1A and
RARb2 were frequently methylated both in primary and
metastatic tissues (range: 55.3%~89.5%). E-cadherin was
not frequently methylated both in primary and meta-
static tissues (range: 18.4%~23.7%). A similar fraction of
methylated genes was observed in the primary cancers
and lymph node metastases, no difference between these
two groups of each gene.
Correlation of methylation in the primary breast cancers
and lymph node metastases
To study whether gene methylation in lymph node
metastases correlated with that in primary cancers, Pear-
son’s correlation coefficient was used to assess the rela-
tionship between two continuous variables. Table 3
displays mean methylation levels for each gene and the
correlation between the two sites. Among these genes,
the methylation status of HIN-1, CDH13, RIL and
RARb2 in lymph nodes metastasis was correlated with
that in primary tumors. The Pearson correlation values
ranged from 0.624 to 0.472 (p values < 0.01 to 0.001).
LINE-1, as a global methylation marker, also correlated
in primary and metastatic tumors. Figure 2 shows the
methylation levels in normal, primary tumor and lymph
nodes metastasis. A statistically significant correlation
was not observed with RASSF1A or with E-cadherin.
To evaluate the expression of 6 genes in primary and
metastatic breast tissues, expression values of those
genes were searched in the dataset originated by the
microarray analysis of Ellsworth et al. [3] on laser
microdissected tumor cells from 20 primary and their
Table 1 Summary of clinical and pathological
characteristics of 38 breast cancer patients
Clinicopathologic factors Number of sample
Age
Mean 59 years
range 35-84 years
Histology
Ductal 28
Lobular 4
Mixed 4
Other 2
Clinical stage
I0
II 12
III 17
IV 9
Tumor size
< 2 cm 11
> 2 cm 27
Grade
I0
II 16
III 22
ER Status
Positive 30
Negative 8
PR status
Positive 23
Negative 15
HER-2/neu primary tumor
Positive 10
Negative 28
HER-2/neu lymph node metastasis
Positive 11
Negative 22
N/A 5
Follow up status
Progression (recurrence, metastasis, death) 14
No evidence of disease 20
Lost to follow-up 4
N/A: not tested
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in the dataset. RASSF1A, RARb2, E-cadherin (CDH1),
CDH13 and RIL were found to be expressed at a low
level, in agreement with the hypermethylation of these
genes in tumor tissues. Expression values of selected
genes ranged from 1.1 to 3302.50 (mean 164.59, SD
372.65), whereas the global gene expression range was
0-47165.60 (mean 708.25, SD 2044.49). The expression
of CDH13, RIL (PDLIM4), RASSF1A,R A R b2a n dE - c a d -
herin (CDH1) in primary tumor and their lymph node
metastasis is compared in Figure 3. CDH13 and RIL
(PDLIM4) expression levels were significantly decreased
in lymph node metastasis, whereas no significantly
changes in the expression of RASSF1A, RARb2 and
CDH1 mRNAs were observed.
Correlation of methylation between different genes
On the basis of data from continuous marker methyla-
tion analyses in primary breast cancer tissues, the
methylation levels of RASSF1A and HIN-1 exhibited a
strong correlation to each other (R = 0.502, p < 0.01).
Some moderate correlations were found between
RASSF1A and CDH13 (R = 0.317, p < 0.01) and between
RASSF1A and RIL (R = 0.497, p < 0.01). Similarly, in
lymph nodes metastasis, a moderate correlation existed
between RASSF1A and RIL (R = 0.489, P< 0.01), CDH13
and E-cadherin (R = 0.391, p< 0.01); RASSF1A and
CDH13 (R = 0.315, p< 0.01).
Relationship between hormone receptor status and
methylation in primary breast cancers and lymph nodes
metastasis
Our pervious study reported that in the primary breast
tumors, the methylation of the HIN-1/RASSFIA panel
strongly correlated positively with the expression of ER,
Figure 1 Pathologic morphology of two frozen primary breast carcinoma (A, C) and their corresponding metastatic axillary lymph
node (B, D) by hematoxylin and eosin staining.
Table 2 Methylation positive rates of 6 tumor suppressor
genes in primary cancer tissues and lymph nodes
metastasis
Genes Number of methylated cases (positive rate %)
Primary cancer Lymph nodes metastasis p value*
HIN-1 28 (73.7) 26 (68.4) 0.508
CDH13 32 (84.2) 34 (89.5) 0.688
RIL 25 (65.8) 25 (65.8) 1.000
RASSF1A 25 (65.8) 24 (63.2) 1.000
RARb2 23 (60.5) 21 (55.3) 0.774
E-cadherin 7 (18.4) 9 (23.7) 0.754
*Binomial exact test for paired comparison.
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CDH13 panel correlated negatively ER, PR, and HR
expression [16]. In this study, we investigated if this asso-
ciation exists in metastatic lymph nodes. By t-Test analy-
sis, it is showed that patients with a positive ER status
had higher methylation levels of HIN-1 in primary
tumors (mean of 41.3 in ER-positive cases versus 15.8 in
ER-negative cases, p = 0.001). Higher methylation levels
of RIL in primary tumors were also found in PR negative
cases (mean of 41.5) when compared with PR positive
cases (mean of 30.5), but no statistical difference was
found, possibly related to the small sample size (Table 4).
Interestingly, we observed an association between hor-
mone status and gene methylation in metastatic lymph
nodes. Patients with a positive ER and PR status had
higher methylation levels of HIN-1 (mean of 35.8 in ER-
positive tumors versus 15.3 in ER-negative tumors, p =
0.008; mean of 38.1 in PR-positive tumors versus 22.5 in
PR-negative tumors, p = 0.047) (Table 5).
Using multivariable logistic regression analysis,
hypermethylation of HIN-1 in primary tumor was sig-
nificantly associated with ER positivity (odds ratio,
1.057; p = 0.027). Hypermethylation of HIN-1 in
metastasis lymph nodes was also significantly asso-
ciated with ER positivivity (odds ratio, 1.070; P =
0.024). Additionally, hypermethylation of HIN-1 in
metastasis lymph nodes was significantly associated
with PR positivity compared with PR negative patients
(odds ratio, 1.046; P = 0.026). Hypermethylation of RIL
in lymph nodes was negatively associated with PR
positivity (odds ratio, 0.964; P = 0.044).
Using multivariable logistic regression models, we
have assessed the correlation of HER-2/neu expression
with methylation of each gene (RIL, HIN-1, RASFF1A,
CDH13, E-cadherin and RARb2). No correlation
between gene methylation and HER-2/neu expression
was found (data not shown).
Relationship between other clinical characteristics and
methylation of individual genes in primary tumors and
lymph nodes metastasis
Among all the genes, CDH13 and E-cadherin methyla-
tion in lymph nodes were positively associated with
age (R = 0.467, 0.435 respectively, p < 0.01). Using the
Logistic regression model, no statistically significant
associations were found for methylation status with clin-
ical stage, tumor size, and grade or tumor progression.
Table 3 Methylation levels of 7 genes in primary breast cancer tissues and lymph nodes metastasis
Genes Normal Methylation level (mean ± SD) Pearson correlation coefficient p value
Primary cancer Lymph nodes metastasis
HIN-1 6.5 ± 3.2 36.4 ± 26.5 33.1 ± 24.2 0.624 < 0.001
CDH13 3.0 ± 1.2 20.0 ± 17.9 20.6 ± 17.5 0.545 < 0.001
RIL 9.1 ± 3.4 34.5 ± 24.6 36.8 ± 26.2 0.547 < 0.001
RASSF1A 4.0 ± 4.7 28.0 ± 19.8 28.3 ± 21.3 0.233 0.16
RARb2 1.1 ± 1.2 16.4 ± 21.6 12.3 ± 18.5 0.472 0.003
E-cadherin 4.0 ± 2.5 7.8 ± 8.8 7.8 ± 9.1 0.093 0.583
LINE-1 66.8 ± 3.4 58.3 ± 9.8 58.3 ± 10.9 0.614 < 0.001
Figure 2 Comparison of methylation levels of 6 genes in normal breast (N), paired primary tumors (P) and metastatic lymph nodes
(M). Mean methylation level of N, P, and M of each group was provided by horizontal lines.
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Page 6 of 10Figure 3 Expression of CDH13, RIL (PDLIM4), RASSF1A, RARb2 and E-cadherin (CDH1) in primary (P) and matched lymph node
metastasis (M) samples from Ellsworth’s study [3]. (A) Heat map of expression levels of the 5 genes analyzed. Gene symbols and probesets
are reported. (B) Box-plot of expression of CDH13 and RIL (PDLIM4) genes in primary tumors and lymph node metastasis. PDLIM4 gene was
recognized by multiple probe sets. P = primary; M = lymph node metastasis.
Table 4 Association of hormone receptors with gene methylation in primary cancers (P)
ER (+) ER (-) p value PR (+) PR (-) p value
HIN-1 (P) 41.3 ± 26.1 15.8 ± 13.2 0.001 40.3 ± 25.0 30.1 ± 27.3 0.232
CDH13 (P) 18.8 ± 18.8 21.0 ± 14.0 0.756 21.0 ± 19.4 16.5 ± 15.2 0.440
RIL (P) 33.2 ± 24.9 41.9 ± 24.1 0.380 30.5 ± 25.3 41.5 ± 23.0 0.171
RASSF1A (P) 29.5 ± 20.5 21.9 ± 17.6 0.340 28.6 ± 20.0 27.0 ± 20.5 0.809
RARb2 (P) 18.2 ± 23.4 11.3 ± 11.6 0.249 17.9 ± 21.2 15.2 ± 22.9 0.706
E-cadherin (P) 7.3 ± 6.6 10.5 ± 15.4 0.602 6.2 ± 4.2 10.4 ± 12.7 0.230
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primary tumors and lymph nodes metastasis
No significant association was found between methyla-
tion status and overall or disease-free survival.
Discussion
Hypermethylation and silencing of specific putative
tumor suppressor genes is clearly observed in a fraction
of human breast cancers, possibly contributing to
uncontrolled growth. Inhibition of DNA methylation
can activate silenced tumor suppressor genes, associated
with the arrest of tumor growth. Our previous study
revealed that five of 12 tumor suppressor genes, RIL,
HIN-1, RASSF1A, CDH13,a n dRARb2, were frequently
methylated in primary breast cancers but not in normal
breast tissue. To determine whether hypermethylation is
also found in lymph node metastasis of breast cancers,
38 pairs of primary breast tumors and lymph node
metastases were selected. In these pairs, the percentage
of malignant cells in primary and metastatic samples
was comparable. Quantitative pyrosequencing was used
to examine the methylation status in these tumors. Our
results indicate that RIL, HIN-1, RASSF1A, CDH13,a n d
RARb2 are also frequently methylated both in primary
breast cancers and in lymph node metastases. The
methylation status of HIN-1, CDH13, RIL, RARb2 in
lymph nodes metastasis were statistically correlated with
that in primary tumors (p values < 0.01 to 0.001). Con-
sequently, metastatic cancer cells retained hypermethyla-
tion and silencing of putative tumor suppressor genes.
As a consequence of hypermethylation status of their
promoters, the frequently methylated genes are expected
to be underexpressed in both primary breast cancer and
lymph node metastasis. Our preliminary quantitative
PCR analysis on tumor and lymph node metastasis sam-
ples showed a very low expression of these genes. By
combining a public dataset [3] containing microarray
data from microdissected tumor cells of 20 primary
tumors and their corresponding lymph node metastasis,
we also observed low expression levels of RASSF1A,
RARß2, CDH13, RIL in the paired samples, suggesting
that hypermetylation of such genes may directly reflects
their gene expression.
The hypermethylation and the preservation of a
restricted expression or a further decreased expression
in lymph node metastasis suggest that the inhibition of
the tumor/invasion suppressor genes is indeed required
for breast cancer progression. Carraway et al. reported
that in the early stage cancer (lymph node negative)
methylation changes can predict the recurrence [19]. In
this study, we studied the methylation status in metasta-
sis lymph nodes and found that methylation changes
which already accumulated in primary cancer were con-
tinued in metastatic tumors. Continued methylation and
silencing of growth inhibitory genes is consistent with
the possibility that inhibitors of DNA methylation might
reactivate their expression and inhibit growth of meta-
static cancer. Our study suggested that DNA methyla-
tion detection in lymph nodes tumors would be a useful
marker for demethylating drugs therapy.
Only a few reports describe the methylation status of
metastatic breast cancer. Metge et al. examinated the
BRMS1 promoter region in a panel of 20 patients sam-
ples and showed that 45% of the primary tumors and
60% of the matched lymph node metastases displayed
hypermethylation of BRMS1 promoter [12]. Mehrotra J
et al. reported that lymph node metastasis exhibited a
somewhat higher prevalence of methylation compared
with the primary breast carcinoma for five genes (Cyclin
D2, RAR-beta, Twist, RASSF1A,a n dHIN-1) with a sta-
tistically significant increase in methylation of HIN-1
(p = 0.04). Compared with the primary breast carcino-
mas, bone, brain, and lung metastasis exhibited higher
methylation frequencies, with HIN-1 and RAR-beta
methylation being significantly higher (p < 0.01) in each
group [13]. These reports were, however, based on non-
quantitative methylation-specific PCR assays. Our study
has used more quantitative techniques, therefore, our
results are more reliable.
Our previous study reported that in the primary breast
tumors, the methylation of HIN-1 and RASSF1A
strongly correlated with the expression of ER, PR, and
HR. Conversely, the methylation of the RIL and CDH13
strongly correlated with lack of ER, PR, and HR expres-
s i o n[ 1 6 ] .I n t e r e s t i n g l y ,i nt h i ss t u d y ,w ef u r t h e rc o n -
firmed that this association also exists in metastatic
Table 5 Association of hormone receptors with gene methylation in lymph nodes metastasis (M)
ER (+) ER (-) p value PR (+) PR (-) p value
HIN-1 (M) 35.8 ± 24.3 15.3 ± 13.9 0.008 38.1 ± 24.7 22.5 ± 19.9 0.047
CDH13 (M) 17.8 ± 14.8 29.4 ± 23.8 0.220 18.8 ± 16.5 22.1 ± 18.6 0.565
RIL (M) 35.0 ± 24.2 42.4 ± 31.6 0.474 31.8 ± 25.3 43.6 ± 25.1 0.155
RASSF1A (M) 24.8 ± 20.0 35.7 ± 26.3 0.203 25.5 ± 21.4 29.2 ± 22.1 0.594
RARb2 (M) 10.2 ± 13.7 18.7 ± 30.7 0.470 11.6 ± 14.7 12.5 ± 22.9 0.881
E-cadherin (M) 8.1 ± 8.6 8.2 ± 11.5 0.975 8.7 ± 9.3 7.1 ± 8.9 0.599
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Page 8 of 10lymph nodes. Using multivariate logistic regression ana-
lysis, hypermethylation of HIN-1 in lymph nodes metas-
tases was significantly associated with ER positive
cancers (odds ratio, 1.070; P = 0.024) and significantly
associated with PR positive cancers (odds ratio, 1.046;
P = 0.026), suggesting that methylation of HIN-1 gene
may controlled by hormone receptors.
Taken together, our data suggest that hypermethyla-
tion and silencing of tumor suppressor genes is carried
from primary breast cancers to lymph node metastases.
Methylation and silencing of suppressor genes in the
primary and metastatic tumors did not correlate with
overall or disease free survival, but this may relate to
the small sample size. A large cohort study may be
required to test the prognostic significance of promoter
methylation.
Conclusions
We used bisulfite pyrosequencing to screen 6 putative
tumor suppressor genes (HIN-1, RASSF1A, RIL, CDH13,
RARb2 and E-cadherin) in 38 pairs of primary breast
tumors and lymph node metastases. Our data indicated
that HIN-1, CDH13, RIL, RASSF1A and RARb2 were fre-
quently methylated both in primary and metastatic tis-
sues. The methylation status of HIN-1, CDH13, RIL, and
RARb2 in lymph nodes metastasis was correlated with
that in primary tumors. This study suggests that hyper-
methylation is extended from primary to metastatic
tumors during tumor progression.
Additional material
Additional file 1: Table S1: Details of clinical and pathological
characteristics of 38 breast cancer patients
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